<DOC>
	<DOCNO>NCT00609219</DOCNO>
	<brief_summary>Patients type cancer call nasopharyngeal cancer . This cancer come back go away high risk come back treatment ( include best treatment know nasopharyngeal cancer ) . We ask patient volunteer research study use special immune system cell call EBV-specific cytotoxic T lymphocytes , new experimental therapy . Most patient nasopharyngeal cancer show evidence infection virus cause infectious mononucleosis , Epstein Barr virus ( EBV ) , time diagnosis nasopharyngeal cancer . EBV find cancer cell patient nasopharyngeal cancer , suggest may play role cause cancer . The cancer cell infect EBV able hide body 's immune system escape destruction . We want see special white blood cell ( call T cell ) train kill EBV-infected cell survive patient 's blood affect tumor . We treat patient different EBV positive cancer variable result . Some patient response treatment . Some patient cure treatment . It possible u predict treatment work nasopharyngeal cancer . The purpose study find large safe dose EBV specific cytotoxic T cell , learn side effect , see whether therapy might help patient nasopharyngeal cancer .</brief_summary>
	<brief_title>T-Lymphocytes Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer , NPC</brief_title>
	<detailed_description>We first test biopsy tumor ( already do ) see tumor cell EBV positive . If patient eligible , take 60-70 ml ( 12-14 teaspoon ) blood . We use blood grow T cell laboratory . We first grow EBV-infected cell line infect blood EBV virus . This line irradiate grow use stimulate T cell . This stimulation train T cell kill cell EBV surface . We grow EBV-specific CTLs stimulation EBV infect cell growth factor call Interleukin 2 . Next , test T cell make sure kill EBV-infected cell . If number T cell produce low , may need obtain additional blood sample make cell . The cell ( patient 's T cell ) inject 10 minute , pretreatment Tylenol Benadryl . A total two dos give two week apart . All Treatments give Center Cell Gene Therapy Texas Children 's Hospital Methodist Hospital . We follow patient clinic injection . To learn way T cell work long last body , extra 10-60 ml ( 2-12 teaspoon ) blood take infusion 3-4 day infusion ( optional ) . Up 40 ml ( 8 teaspoon ) blood also draw 1 , 2 , 4 6 week post-infusion , 3 , 6 , 9 , 12 month . The blood may draw patient 's central line time regular blood test . We use blood look immune response patient 's cancer . Over course study , 29 tablespoon blood drawn . Patients also repeat scan 8 week first injection . If show stable improve disease may ( patient wish ) receive 6 extra dos cell . These would give every 1-3 month . If patient additional injection cell first two infusion , take extra blood test infusion , end infusion , 3-4 day infusion ( day optional depend patient preference ) , 1 2 week infusion . We also extra scan 1 3 month last infusion . Follow continue every 3 month continue 12 month last infusion .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>All patient NPC first subsequent relapse primary refractory disease high risk ( T3 T4 , node positive disease ) EBV genome antigen demonstrate tissue biopsy eligible trial . Patients life expectancy &gt; 6 week Patients Karnofsky score &gt; /= 50 No severe intercurrent infection . Patient , parent/guardian able give inform consent . Patients bilirubin &lt; 2x normal , SGOT &lt; 3x normal , Hgb &gt; 8.0 Patients creatinine &lt; 2x normal age Patients investigational therapy one month prior entry study . Patients life expectancy &lt; 6 week . Patients Karnofsky score &lt; 50 . Patients severe intercurrent infection . Patient , parent/guardian unable give inform consent . Patients bilirubin &gt; 2x normal . SGOT &gt; 3x normal abnormal prothrombin time . Patients creatinine &gt; 2x normal age Due unknown effect therapy fetus , pregnant woman exclude research . The male partner use condom . Note : Patients would exclude protocol strictly laboratory abnormality include investigator discretion approval CAGT Protocol Review Committee FDA reviewer .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>recurrent nasopharyngeal cancer</keyword>
	<keyword>stage II nasopharyngeal cancer</keyword>
	<keyword>stage III nasopharyngeal cancer</keyword>
	<keyword>stage IV nasopharyngeal cancer</keyword>
</DOC>